244 related articles for article (PubMed ID: 23141566)
1. Human leukocyte antigen-associated drug hypersensitivity.
Illing PT; Vivian JP; Purcell AW; Rossjohn J; McCluskey J
Curr Opin Immunol; 2013 Feb; 25(1):81-9. PubMed ID: 23141566
[TBL] [Abstract][Full Text] [Related]
2. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex.
Bharadwaj M; Illing P; Theodossis A; Purcell AW; Rossjohn J; McCluskey J
Annu Rev Pharmacol Toxicol; 2012; 52():401-31. PubMed ID: 22017685
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of hypersensitivity drug reactions.
Negrini S; Becquemont L
Therapie; 2017 Apr; 72(2):231-243. PubMed ID: 28162244
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte antigens and drug hypersensitivity.
Chung WH; Hung SI; Chen YT
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
[TBL] [Abstract][Full Text] [Related]
5. HLA alleles and drug hypersensitivity reactions.
Profaizer T; Eckels D
Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
[TBL] [Abstract][Full Text] [Related]
6. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.
Chessman D; Kostenko L; Lethborg T; Purcell AW; Williamson NA; Chen Z; Kjer-Nielsen L; Mifsud NA; Tait BD; Holdsworth R; Almeida CA; Nolan D; Macdonald WA; Archbold JK; Kellerher AD; Marriott D; Mallal S; Bharadwaj M; Rossjohn J; McCluskey J
Immunity; 2008 Jun; 28(6):822-32. PubMed ID: 18549801
[TBL] [Abstract][Full Text] [Related]
7. Genetics and the potential for predictive tests in adverse drug reactions.
Pirmohamed M
Chem Immunol Allergy; 2012; 97():18-31. PubMed ID: 22613851
[TBL] [Abstract][Full Text] [Related]
8. [HLA-B*5701 and abacavir hypersensitivity reaction].
Servonnet A; Leclercq E; Delacour H; Ceppa F
Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
[TBL] [Abstract][Full Text] [Related]
9. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome.
Llano A; Brander C
Cell Res; 2012 Dec; 22(12):1637-9. PubMed ID: 22777424
[TBL] [Abstract][Full Text] [Related]
11. The structural basis of HLA-associated drug hypersensitivity syndromes.
Pompeu YA; Stewart JD; Mallal S; Phillips E; Peters B; Ostrov DA
Immunol Rev; 2012 Nov; 250(1):158-66. PubMed ID: 23046128
[TBL] [Abstract][Full Text] [Related]
12. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
[TBL] [Abstract][Full Text] [Related]
13. [The associations between idiosyncratic adverse drug reactions and HLA alleles and their underlying mechanism].
Wang Q; Mei H; Zhang YL; Pan XC; Tan W; Chao L
Yao Xue Xue Bao; 2013 Jun; 48(6):799-808. PubMed ID: 23984511
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic information derived from analysis of HLA alleles.
Gatanaga H; Honda H; Oka S
Pharmacogenomics; 2008 Feb; 9(2):207-14. PubMed ID: 18370849
[TBL] [Abstract][Full Text] [Related]
15. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
[TBL] [Abstract][Full Text] [Related]
16. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
[TBL] [Abstract][Full Text] [Related]
17. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
Waters LJ; Mandalia S; Gazzard B; Nelson M
AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
[TBL] [Abstract][Full Text] [Related]
18. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
Lucas A; Nolan D; Mallal S
J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
Kaniwa N; Saito Y
J Hum Genet; 2013 Jun; 58(6):317-26. PubMed ID: 23635947
[TBL] [Abstract][Full Text] [Related]
20. Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.
Gerogianni K; Tsezou A; Dimas K
Mol Diagn Ther; 2018 Jun; 22(3):297-314. PubMed ID: 29564734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
